Ben Haas

Partner at Latham & Watkins LLP

Ben Haas

Ben Haas

Partner at Latham & Watkins LLP

Biography

Ben Haas practices in Latham & Watkins’ Washington, D.C. office, where he is a corporate partner in the Healthcare and Life Sciences Practice Group. Mr. Haas focuses his practice on regulatory, transactional and legislative matters involving the medical device, pharmaceutical, biotechnology, tobacco, food, cosmetic and dietary supplement industries. Mr. Haas has counseled clients on a wide variety of regulatory matters involving the US Food and Drug Administration (FDA), including, among others:

Pre-market product development and clinical and pre-clinical testing
FDA submissions
Product promotion and labeling
Compliance with good manufacturing practice requirements
Agency inspections and recalls.

In the transactional area, Mr. Haas provides counsel on corporate compliance, mergers and acquisitions, and other corporate transactions. He regularly assists FDA-regulated device companies in initiating, managing and completing large, international clinical trials. He has counseled clients regarding clinical trial strategy; contracting with and managing clinical research organizations, other clinical trial vendors, and clinical trial sites and investigators in the US and in dozens of overseas jurisdictions; and communicating with US and foreign regulatory authorities, as well as institutional review boards and ethics committees, both domestic and foreign. Mr. Haas has also drafted and negotiated several types of agreements for healthcare clients, including manufacturing and supply, licensing, joint development, consulting and marketing and distribution contracts. Finally, Mr. Haas has conducted regulatory diligence for major public and private financings, mergers and other transactions in the device, pharmaceutical, biotechnology and dietary supplement industries.

Mr. Haas also counsels clients on legislative and administrative rulemaking proceedings relating to the FDA, including issues resulting from the implementation of the Family Smoking Prevention and Tobacco Control Act of 2009, the Food and Drug Administration Amendments Act of 2007, the Medical Device User Fee and Modernization Act of 2002, the Bioterrorism Act of 2002, and the Medicare Prescription Drug Improvement and Modernization Act of 2003. He has also worked with trade associations and other clients to address specific regulatory issues in matters before several federal agencies, including the Environmental Protection Agency, Federal Trade Commission, Department of Transportation, US Department of Agriculture and Drug Enforcement Administration.

Mr. Haas has authored and co-authored articles on FDA regulatory matters, including articles in the Food and Drug Law Institute's Update Magazine and the Pharmaceutical Law & Industry Report, and has been a featured speaker and lecturer on FDA regulatory and policy matters at industry-sponsored events.

Mr. Haas also served as a member of the Latham's Global Training and Career Enhancement Committee.

Some of Mr. Haas' recent publications include:

“FDA to Strengthen Oversight of Certain In Vitro Diagnostic Devices,” Latham & Watkins Client Alert (August 2014)
“Medical Device IDEs: FDA Continues Effort Toward Greater Efficiency and Transparency,” Latham & Watkins Client Alert (July 2013)
“FDA Issues Draft Guidance on Expedited Review Programs, Including Breakthrough Therapy Designations,” Latham & Watkins Client Alert (July 2013)
“EU Proposes Overhaul of Clinical Trial Procedures,” Latham & Watkins Client Alert (July 2012)
“Medical Device Benefit-Risk Determinations: FDA Releases a Novel Guidance Giving Industry an Inside View of Agency Decision-Making,” Latham & Watkins Client Alert (April 2012)
“FDA Issues Draft Guidance for In Vitro Companion Diagnostic Devices,” Latham & Watkins Client Alert (July 2011)
"FDA Moves to Clarify Nanotechnology Guidelines,” Latham & Watkins Client Alert (June 2011)
“Supreme Court Holds That Bayh-Dole Act Does Not Automatically Strip Employees Of Rights In Their Federally Funded Inventions,” Latham & Watkins Client Alert (June 2011)
“An Ounce of Prevention: FDA Issues First Rules Under FSMA Intended to Prevent Unsafe Food from Entering the Market,” Latham & Watkins Client Alert (June 2011)
“Matrixx Initiatives, Inc. v. Siracusano: Changes in Adverse Event Reporting,” Latham & Watkins Client Alert (April 2011)
“Medical Device Reform Is (Almost) Here: FDA Announces Action Items for Improving The Agency’s 510(k) Premarket Clearance Process,” BNA’s Medical Devices Law & Industry Report (March 2011)
“FDA Announces Actions Designed to Improve the 510(k) Premarket Clearance Process,” Latham & Watkins Client Alert (January 2011)
“FDA Revises Informed Consent Regulations to Incorporate Clinical Trial Registration Requirements,” Latham & Watkins Client Alert (January 2011)
“FDA Revises Safety Reporting Requirements for Investigational New Drug and Bioavailability and Bioequivalence Studies,” Latham & Watkins Client Alert (November 2010)
“Not Yet: Patented Risk Evaluation and Mitigation Strategies May Delay (or Tax) Competitors,” Intellectual Property Today (June 2009)
“The Web of Clinical Trial Registration Obligations: Have Foreign Clinical Trials Been Caught?” Food and Drug Law Journal, Vol. 64 No. 2 (June 2009)
“FDA Issues Clarification of US Clinical Trials Registry Requirements,” Latham & Watkins Client Alert (January 2009)
“Looking Abroad: Clinical Drug Trials,” Food and Drug Law Journal, Vol. 63, No. 3 (September 2008)
“Increased Scrutiny of Investor Communications by Federal Regulators,” FDLI’s Update Magazine (January 2006)
“FDA-SEC Initiative May Signal Increased Scrutiny of Investor Communications,” Latham & Watkins Client Alert (March 2004)
“Associates’ Corner: FDA Issues Guidance on Pharmacogenomic Data,” Latham & Watkins Client Alert (March 2004)

Overview
RelSci Relationships

2325

Number of Awards

2

Relationships
RelSci Relationships are individuals Ben Haas likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chair, Strategic Client Initiative at Latham & Watkins LLP

Relationship likelihood: Strong

Partner at Latham & Watkins LLP

Relationship likelihood: Strong

Office Managing Partner, San Francisco at Latham & Watkins LLP

Relationship likelihood: Strong

Global Chair, International Tax Practice at Latham & Watkins LLP

Relationship likelihood: Strong

Partner at Latham & Watkins LLP

Relationship likelihood: Strong

Partner at Latham & Watkins LLP

Relationship likelihood: Strong

Partner at Latham & Watkins LLP

Relationship likelihood: Strong

Deputy Office Managing Partner at Latham & Watkins LLP

Relationship likelihood: Strong

Deputy General Counsel at Latham & Watkins LLP

Relationship likelihood: Strong

Global Chair, Consumer Class Action Practice Group at Latham & Watkins LLP

Relationship likelihood: Strong

In The News
The Deal Pipeline
January 6, 2016
NuVasive returns to M&A game with Ellipse buy
The Deal Pipeline
February 24, 2014
Cinven buys Medpace from CCMP
The Deal Pipeline
July 18, 2013
OncoMed IPO goes metastatic
Paths to Ben Haas
Potential Connections via
Relationship Science
You
Ben Haas
Partner at Latham & Watkins LLP
Education
JD
Class of 2001

Founded by Thomas Jefferson in 1819, the University of Virginia School of Law is a world-renowned training ground for distinguished lawyers and public servants. Consistently ranked among the top law schools in the nation, Virginia has educated generations of lawyers, instilling in them a commitment to leadership, integrity and community service. Virginia is justly famous for its collegial environment that bonds students and faculty, and student satisfaction is consistently cited as among the highest in American law schools. At Virginia, law students share their experiences in a cooperative spirit, both in and out of the classroom, and build a network that lasts well beyond their three years here. With more than 20,000 students and a faculty of more than 2,100, the University of Virginia has been ranked first or second among the nation's public universities since 1984. The University's diverse intellectual life is open to law students: Up to 12 credits from other departments may be counted toward the J.D. degree.

BS
Class of 1997

Georgetown University is a private research university in Washington, D.C. Founded in 1789, it is the oldest Jesuit and Catholic university in the United States. Georgetown's main campus, located in Washington's Georgetown neighborhood, is noted for Healy Hall, a National Historic Landmark in the Romanesque revival style. Georgetown operates a law center on Capitol Hill and auxiliary campuses in Italy, Turkey, and Qatar.

Career History
Partner
Current

Latham & Watkins LLP is a full-service law firm. The firm offers services in the areas of finance, litigation, tax, banking, life sciences, private equity, real estate, government relations, employment law, and outsourcing. The firm practices in a spectrum of transactional, litigation, corporate, and regulatory areas. Latham & Watkins was established in 1934 and is based in New York, New York.

Transactions
Details Hidden

Impax Laboratories LLC purchases Amneal Pharmaceuticals LLC from Ae Cos. LLC resulting in a new company Amneal Pharmaceuticals, Inc.

Details Hidden

Baxter International, Inc. purchases Servier IP UK Ltd. from ESSETIFIN SpA

Details Hidden

Mallinckrodt Plc purchases Mallinckrodt Hospital Products, Inc.

Awards & Honors
Admitted to District of Columbia Bar
Admitted to the Virginia Bar
Other Affiliations

Ben Haas is affiliated with Latham & Watkins LLP

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ben Haas. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ben Haas's profile does not indicate a business or promotional relationship of any kind between RelSci and Ben Haas.